Loading clinical trials...

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine® | Clinical Trials | Clareo Health

RECRUITINGNA

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®

NCT02354274•Olfred Hansen

View on ClinicalTrials.gov

Summary

To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread

Detailed Description

To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET-positive areas compared to a standard homogeneous dose spread.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB
•Performance status 0-1
•Able to comply with treatment and follow study and follow-up procedures
•Women must have negative pregnancy test
•Signed, informed consent
•Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available

Exclusion Criteria

•Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease)
•Need for nasal oxygen
•Former thoracic radiotherapy, unless there is no significant overlap with previous fields
•Any other active malignant disease
•Unable to take oral medications or needing intravenous nutrition
•Ulcer
•Nursing women

Locations (7)

Aalborg University Hospital

Aalborg, Denmark

Aarhus University Hospital

Aarhus, Denmark

Rigshospitalet

Copenhagen, Denmark

Herlev University Hospital

Herlev, Denmark

Department of Oncology, Naestved Hospital

Næstved, Denmark

Department of Oncology, Odense University Hospital

Odense, Denmark

Department of Oncology, Vejle Hospital

Vejle, Denmark

Key Dates

Start Date

January 1, 2015

Primary Completion Date

October 1, 2029

Completion Date

October 1, 2029

Last Updated

April 25, 2022

Enrollment

330

ESTIMATED participants

Conditions

NSCLC

Interventions

Escalated: Inhomogeneous dose plan

RADIATION

Standard: Homogeneous dose plan

RADIATION

Contacts

Olfred Hansen, MD

CONTACT

+4565411867 olfred.hansen@rsyd.dk

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITINGPHASE3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE1/PHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 25, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

Inclusion Criteria

Exclusion Criteria

Magnetic Resonance Imaging of the Lung: Oncological Applications

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed